All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub Satellite Symposium at 15-ICML brought together an international panel of experts to discuss the novel chemotherapy-free treatment approaches for lymphoid malignancies. Professor Simon Rule, Derriford Hospital Plymouth Hospitals NHS Trust, Plymouth, UK, focused on mantle cell lymphoma (MCL), navigating the rapidly evolving treatment landscapes.
Chemo-free approaches in MCL- presentation
He began by reviewing how MCL patients were treated historically with R-CHOP or rituximab + bendamustine (R-Benda) in both, front-line and the relapsed/refractory (R/R) settings. Young and fit patients received autologous stem cell transplantation (ASCT) before undergoing allogeneic stem cell transplantation (allo-SCT) at first relapse. He highlighted the need to rethink treatment for MCL with the advent of ibrutinib, which is particularly efficacious in patients who have received only one prior therapy.
Durable responses lasting more than 2 years can be achieved in 50% of patients with ibrutinib as a monotherapy. Despite advocating for ibrutinib to be used as a second-line treatment in all patients, he pointed out that in the high-risk group of younger, fit patients with a p53 mutation, ibrutinib should merely be used as a bridging therapy before allo-SCT due to their high risk of relapse. As part of combination therapy (for example, RLI), high ORR and complete response (CR) have been demonstrated in patients with relapsed MCL (regardless of p53 type). Furthermore, the AIM trial showed similar benefits of ibrutinib in combination with venetoclax for newly diagnosed MCL patients.
Prof. Rule went on to discuss novel therapies being used for front-line treatment of MCL. He mentioned the Lyma-101 trial (the results of which were presented at the 24th European Hematology Association Congress, summarised on lymphoma hub here), which assessed obinutuzumab and dexamethasone, high dose cytarabine and cisplatin (O-DHAP) followed by consolidation therapy with ASCT, and obinutuzumab maintenance for three years.
Lyma-101 found acceptable toxicity, good OS, and PFS. Though longer-term follow up is still ongoing. Prof. Rule also mentioned Window I/II, a trial with ibrutinib and rituximab induction, followed by a short intensive chemo-immunotherapy course. He also talked about studies assessing the combination of lenalidomide and rituximab, or obinutuzumab, venetoclax and ibrutinib in older patients.
In his concluding remarks, Prof. Rule stressed the significance of ibrutinib treatment for most patients with relapsed MCL, and recommended it as a standard of care. When questioned, Prof. Rule highlighted his preferred maintenance regimens: in younger patients, rituximab maintenance given after chemo or allo-SCT, in older patients, rituximab maintenance should only be considered after R-CHOP, but not after R-Benda due to a lack of benefit.
Download Prof. Simon Rule's slides:
These slides were presented by Prof. Simon Rule during the first Lymphoma Hub Satellite Symposium at 15-ICML.Download as PDF
New chemotherapy-free approaches for the treatment of lymphoid malignancies
At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...
What was new in MCL at ASCO and EHA 2020?
Interview with Simon Rule, Derriford Hospital. We asked, What was new in mantle cell lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox